<DOC>
	<DOCNO>NCT02791243</DOCNO>
	<brief_summary>This study evaluate potential induction photosensitization P-3074 0.25 % finasteride cutaneous solution compare placebo vehicle cutaneous solution negative control ( 0.9 % sodium chloride , NaCl )</brief_summary>
	<brief_title>Photosensitization Study Androgenetic Alopecia</brief_title>
	<detailed_description>Healthy male volunteer , draw general population , treat P-3074 solution , placebo vehicle control 0.9 % sodium chloride USP ( negative control ) use 6 induction application back area Ultraviolet A ( UVA ) /Ultraviolet B ( UVB ) irradiation 3 week induction period , 10 day rest period , challenge phase 24-hour patch application , UVA UVB irradiation follow evaluation photosensitization subsequent 72 hour .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Photosensitivity Disorders</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>1 . Males age 18 65 . 2 . Good general health , assess verbal medical history brief physical examination skin . 3 . Fitzpatrick Skin Type IIV , determine interview screening . 4 . Willing use doublebarrier method ( example , condom diaphragm plus spermicide ) sexual intercourse female partner participate study . 5 . Male subject need confirm method length time method birth control female partner . 6 . Fully informed risk enter study willing provide write consent enter study . 7 . Willing follow study rule , include : sun exposure ( example , swimming , sunbathing , tan bed ) , avoidance activity would cause excessive sweating , use lotion , cream , oil back area 8 . Must willing change current brand personal care product soap , body wash , laundry detergent , body spray , body spritz , etc . participate study . 1 . MED ≤ 2.5 SED Fitzpatrick Skin Types I II MED ≤ 4.0 SED Fitzpatrick Skin Types III IV 2 . Type I Insulindependent diabetes 3 . Mastectomy cancer involve removal lymph node drain test site . 4 . Clinically significant skin disease may contraindicate participation , include psoriasis , eczema , atopic dermatitis , active skin cancer . 5 . Use photosensitizing medication supplement , limited sulfa drug , tetracycline , phenothiazine , thiazide , antiemetic St. John 's Wort . 6 . Any medical condition cause affected sunlight ( UV ) , limited solar urticarial polymorphous light eruption . 7 . Active immunologic disorder . 8 . Routine use antiinflammatory , immunosuppressive antihistamine medication ( 81 mg aspirin acceptable ) . 9 . Participation patch test soap chamber test within past 4 week . 10 . History significant sensitivity allergy adhesive bandage , tape , etc . 11 . Use finasteride ( oral and/or topical ) , within 6 month prior screen visit . 12 . Contraindications finasteride therapy intolerance finasteride . 13 . History sensitivity skin solution product . 14 . Hair , tattoo , pigmentation , scar , mole condition area patch may interfere patch application , tolerability , postapplication evaluation . 15 . Participation clinical trial receipt investigational medication within 4 week study . 16 . Current treatment allergy injection . 17 . History severe asthma . 18 . Chronic active liver disease [ alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5x upper limit normal ( ULN ) ] 19 . Neutrophils &lt; 1500 cells/mm3 20 . Clinically significant chronic illness , could place subject increase risk participation result inappropriate dermal response study opinion Investigator . 21 . History alcohol drug abuse within 1 year study . 22 . Any condition Investigator believe would interfere evaluation subject , may put subject undue risk . 23 . Judged investigator unsuitable reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>